Ophthalmology Therapeutics
1. Durezol patent expiration
Treatment: NA
DUREZOL IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6114319 (Pediatric) | SANDOZ | Compositions containing difluprednate |
Nov, 2019
(6 years ago) | |
| US6114319 | SANDOZ | Compositions containing difluprednate |
May, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2013 |
| New Indication(I-653) | Jun 13, 2015 |
| M(M-127) | Mar 22, 2016 |
| Pediatric Exclusivity(PED) | Sep 22, 2016 |
| Orphan Drug Exclusivity(ODE) | Jun 13, 2019 |
| Orphan Drug Exclusivity(ODE-26) | Jun 13, 2019 |
Drugs and Companies using DIFLUPREDNATE ingredient
NCE-1 date: 23 September, 2015
Market Authorisation Date: 23 June, 2008
Dosage: EMULSION
How can I launch a generic of DUREZOL before it's drug patent expiration?
More Information on Dosage
DUREZOL family patents
2. Izervay patent expiration
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by administerting avacincaptad pegol to the eye
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10947544 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(1 year, 7 days ago) | |
| US7803931 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(1 year, 7 days ago) | |
| US7538211 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(1 year, 7 days ago) | |
| US9617546 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2027
(11 months from now) | |
| US7579456 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2027
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11491176 | ASTELLAS | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(8 years from now) | |
| US11273171 | ASTELLAS | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(8 years from now) | |
| US8236773 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Nov, 2026
(8 months from now) | |
| US12016875 | ASTELLAS | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(8 years from now) | |
Drugs and Companies using AVACINCAPTAD PEGOL SODIUM ingredient
Market Authorisation Date: 04 August, 2023
Dosage: SOLUTION
More Information on Dosage
IZERVAY family patents
3. Lastacaft patent
expiration
Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5468743 | ABBVIE | Imidazo[2,1-b]benzazepine derivatives, compositions and method of use |
Nov, 2013
(12 years ago) | |
| US8664215 | ABBVIE | Ocular allergy treatments with alcaftadine |
Dec, 2027
(1 year, 9 months from now) | |
| US10617695 | ABBVIE | Ophthalmic compositions containing alcaftadine |
Mar, 2027
(1 year, 25 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 28, 2015 |
Drugs and Companies using ALCAFTADINE ingredient
NCE-1 date: 28 July, 2014
Market Authorisation Date: 28 July, 2010
Dosage: SOLUTION/DROPS
How can I launch a generic of LASTACAFT before it's drug patent expiration?
More Information on Dosage
LASTACAFT family patents
4. Lumigan patent expiration
Treatment: Lumigan is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; A method of lowering intraocular pressure; M...
LUMIGAN's oppositions filed in EPO
LUMIGAN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7851504 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5688819 | ABBVIE | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Aug, 2014
(11 years ago) | |
| US6403649 | ABBVIE | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep, 2012
(13 years ago) | |
| US8017655 | ABBVIE | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov, 2012
(13 years ago) | |
| US9155716 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(11 months ago) | |
| US9241918 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(11 months ago) | |
| US8299118 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(11 months ago) | |
| US8309605 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(11 months ago) | |
| US8338479 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(11 months ago) | |
| US8524777 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(11 months ago) | |
| US8586630 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(11 months ago) | |
| US8278353 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(11 months ago) | |
| US8933127 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(11 months ago) | |
| US8933120 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(11 months ago) | |
| US8772338 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 31, 2013 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 16 March, 2001
Dosage: SOLUTION/DROPS
How can I launch a generic of LUMIGAN before it's drug patent expiration?
More Information on Dosage
LUMIGAN family patents
5. Macugen patent expiration
Treatment: Treatment of vegf mediated ocular disease.
MACUGEN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6051698 | BAUSCH | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
May, 2015
(10 years ago) | |
| US6113906 | BAUSCH | Water-soluble non-antigenic polymer linkable to biologically active material |
Oct, 2013
(12 years ago) | |
| US5919455 | BAUSCH | Non-antigenic branched polymer conjugates |
Oct, 2013
(12 years ago) | |
| US6011020 | BAUSCH | Nucleic acid ligand complexes |
Jan, 2017
(9 years ago) | |
| US5932462 | BAUSCH | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
Aug, 2016
(9 years ago) | |
Drugs and Companies using PEGAPTANIB SODIUM ingredient
Market Authorisation Date: 17 December, 2004
Dosage: INJECTABLE
More Information on Dosage
MACUGEN family patents
6. Miebo patent expiration
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
MIEBO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10576154 | BAUSCH | Semifluorinated alkane compositions |
Oct, 2035
(9 years from now) | |
| US10507132 | BAUSCH | Topical administration method |
Jun, 2037
(11 years from now) | |
| US10449164 | BAUSCH | Methods of treating ocular disorders using semifluorinated alkanes |
Sep, 2033
(7 years from now) | |
| US10369117 | BAUSCH | Compositions comprising mixtures of semifluorinated alkanes |
Sep, 2033
(7 years from now) | |
| US10058615 | BAUSCH | Semifluorinated alkane compositions |
Sep, 2033
(7 years from now) | |
| US11357738 | BAUSCH | Semifluorinated compounds and their compositions |
Sep, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 18, 2028 |
Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient
NCE-1 date: 19 May, 2027
Market Authorisation Date: 18 May, 2023
Dosage: SOLUTION/DROPS
More Information on Dosage
MIEBO family patents
7. Nevanac patent expiration
Treatment: Method of treating ocular inflammation
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5475034 | HARROW EYE | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
Jun, 2014
(11 years ago) | |
| US7834059 | HARROW EYE | Topical nepafenac formulations |
Jan, 2027
(11 months from now) | |
| US8071648 | HARROW EYE | Topical nepafenac formulations |
Dec, 2025
(2 months ago) | |
| US8324281 | HARROW EYE | Topical nepafenac formulations |
Dec, 2025
(2 months ago) | |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 19 August, 2005
Dosage: SUSPENSION/DROPS
More Information on Dosage
NEVANAC family patents
8. Omlonti patent expiration
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10774072 | OCUVEX | Crystal of N-substituted sulfonamide compound |
Jun, 2035
(9 years from now) | |
| US8648097 | OCUVEX | Pyridylaminoacetic acid compound |
Oct, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11666563 | OCUVEX | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
Jul, 2039
(13 years from now) | |
| US11197849 | OCUVEX | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(8 years from now) | |
| US10702511 | OCUVEX | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(8 years from now) | |
| US10179127 | OCUVEX | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(8 years from now) | |
| US9415038 | OCUVEX | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(8 years from now) | |
| USRE48183 | OCUVEX | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(8 years from now) | |
| US11793798 | OCUVEX | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(8 years from now) | |
| US8685986 | OCUVEX | Medical composition for treatment or prophylaxis of glaucoma |
Oct, 2029
(3 years from now) | |
| US10765750 | OCUVEX | Pharmaceutical composition containing pyridylaminoacetic acid compound |
Jan, 2035
(8 years from now) | |
| US12295946 | OCUVEX | Pharmaceutical Formulations Comprising A Pyridylaminoacetic Acid Compound |
Jan, 2035
(8 years from now) | |
| US12290511 | OCUVEX | Pharmaceutical Preparation Containing Pyridyl Aminoacetic Acid Compound |
Dec, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: 22 September, 2026
Market Authorisation Date: 22 September, 2022
Dosage: SOLUTION
More Information on Dosage
OMLONTI family patents
9. Rhopressa patent expiration
Treatment: Reduction of elevated intraocular pressure
RHOPRESSA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8450344 | ALCON | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(4 months from now) | |
| US9096569 | ALCON | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(4 months from now) | |
| US10174017 | ALCON | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(3 years from now) | |
| US8394826 | ALCON | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(4 years from now) | |
| US9931336 | ALCON | Combination therapy |
Mar, 2034
(8 years from now) | |
| US10654844 | ALCON | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(3 years from now) | |
| US10588901 | ALCON | Combination therapy |
Mar, 2034
(8 years from now) | |
| US9415043 | ALCON | Combination therapy |
Mar, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10532993 | ALCON | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(4 months from now) | |
| US11021456 | ALCON | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(4 months from now) | |
| US11028081 | ALCON | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(3 years from now) | |
| US10882840 | ALCON | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(4 months from now) | |
| US11618748 | ALCON | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(3 years from now) | |
| US11020385 | ALCON | Combination therapy |
Mar, 2034
(8 years from now) | |
| US11185538 | ALCON | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2022 |
Drugs and Companies using NETARSUDIL MESYLATE ingredient
NCE-1 date: 18 December, 2021
Market Authorisation Date: 18 December, 2017
Dosage: SOLUTION/DROPS
How can I launch a generic of RHOPRESSA before it's drug patent expiration?
More Information on Dosage
RHOPRESSA family patents
10. Travatan patent expiration
Treatment: Method of stabilizing prostaglandin; Method for treating glaucoma and ocular hypertension
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5631287 | ALCON | Storage-stable prostaglandin compositions |
Dec, 2014
(11 years ago) | |
| US6011062 | ALCON | Storage-stable prostaglandin compositions |
Dec, 2014
(11 years ago) | |
| US5510383 | ALCON | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
Aug, 2013
(12 years ago) | |
| US5889052 | ALCON | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
Dec, 2014
(11 years ago) | |
| US5849792 | ALCON | Storage-stable prostaglandin compositions |
Dec, 2014
(11 years ago) | |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 16 March, 2001
Dosage: SOLUTION/DROPS
How can I launch a generic of TRAVATAN before it's drug patent expiration?
More Information on Dosage
TRAVATAN family patents
11. Visudyne patent expiration
Treatment: Use of the drug product in photodynamic therapeutic protocols for the treatment of age-related macular degeneration and related conditions involving unwanted neovasculature in the eye
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5756541 | BAUSCH | Vision through photodynamic therapy of the eye |
Mar, 2016
(9 years ago) | |
| US5770619 | BAUSCH | Method of activating photosensitive agents |
Jan, 2015
(11 years ago) | |
| US5798349 | BAUSCH | Use of green porphyrins to treat neovasculature in the eye |
Aug, 2015
(10 years ago) | |
| US5707608 | BAUSCH | Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer |
Aug, 2015
(10 years ago) | |
Drugs and Companies using VERTEPORFIN ingredient
Market Authorisation Date: 12 April, 2000
Dosage: INJECTABLE
More Information on Dosage
VISUDYNE family patents
12. Vizz patent expiration
Treatment: Treatment of presbyopia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12414942 | LENZ | NA |
Mar, 2044
(18 years from now) | |
| US10052313 | LENZ | Compositions And Methods For The Treatment Of Presbyopia |
Mar, 2034
(8 years from now) | |
| US11179328 | LENZ | Compositions And Methods For The Treatment Of Presbyopia |
Mar, 2034
(8 years from now) | |
| US12128036 | LENZ | Compositions And Methods For Storage Stable Ophthalmic Drugs |
Oct, 2039
(13 years from now) | |
| US9844537 | LENZ | Compositions And Methods For The Treatment Of Presbyopia |
Mar, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2030 |
Drugs and Companies using ACECLIDINE HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2029
Market Authorisation Date: 31 July, 2025
Dosage: SOLUTION/DROPS
More Information on Dosage
VIZZ family patents
13. Vyzulta patent expiration
Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension
VYZULTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6211233 | BAUSCH | Prostaglandin pharmaceutical compositions |
Jun, 2018
(7 years ago) | |
| US7910767 | BAUSCH | Prostaglandin derivatives |
Jan, 2025
(1 year, 1 month ago) | |
| US8058467 | BAUSCH | Prostaglandin derivatives |
Feb, 2029
(3 years from now) | |
| US7273946 | BAUSCH | Prostaglandin derivatives |
Oct, 2025
(4 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7629345 | BAUSCH | Prostaglandin derivatives |
Jan, 2025
(1 year, 1 month ago) | |
Drugs and Companies using LATANOPROSTENE BUNOD ingredient
Market Authorisation Date: 02 November, 2017
Dosage: SOLUTION/DROPS
How can I launch a generic of VYZULTA before it's drug patent expiration?
More Information on Dosage
VYZULTA family patents
14. Xiidra patent expiration
Treatment: Treatment of signs and symptoms of dry eye disease (ded); Treatment of the signs and symptoms of dry eye disease (ded)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7928122 | BAUSCH | Modulators of cellular adhesion |
Nov, 2024
(1 year, 3 months ago) | |
| US7745460 | BAUSCH | Modulators of cellular adhesion |
Nov, 2024
(1 year, 3 months ago) | |
| US9890141 | BAUSCH | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(4 years from now) | |
| US7314938 | BAUSCH | Modulators of cellular adhesion |
Mar, 2025
(11 months ago) | |
| US8084047 | BAUSCH | Compositions and methods for treatment of eye disorders |
May, 2026
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8592450 | BAUSCH | Compositions and methods for treatment of eye disorders |
May, 2026
(2 months from now) | |
| US8367701 | BAUSCH | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(3 years from now) | |
| US9216174 | BAUSCH | Modulators of cellular adhesion |
Nov, 2024
(1 year, 3 months ago) | |
| US7790743 | BAUSCH | Modulators of cellular adhesion |
Nov, 2024
(1 year, 3 months ago) | |
| US8168655 | BAUSCH | Compositions and methods for treatment of eye disorders |
May, 2029
(3 years from now) | |
| US10124000 | BAUSCH | Modulators of cellular adhesion |
Nov, 2024
(1 year, 3 months ago) | |
| US9447077 | BAUSCH | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(3 years from now) | |
| US8927574 | BAUSCH | Crystalline pharmaceutical and methods of preparation and use thereof |
Nov, 2030
(4 years from now) | |
| US9085553 | BAUSCH | LFA-1 inhibitor and methods of preparation and polymorph thereof |
Jul, 2033
(7 years from now) | |
| US11058677 | BAUSCH | LFA-1 inhibitor formulations |
Dec, 2033
(7 years from now) | |
| US9353088 | BAUSCH | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 11, 2021 |
Drugs and Companies using LIFITEGRAST ingredient
NCE-1 date: 11 July, 2020
Market Authorisation Date: 11 July, 2016
Dosage: SOLUTION/DROPS
How can I launch a generic of XIIDRA before it's drug patent expiration?
More Information on Dosage
XIIDRA family patents
15. Zioptan patent expiration
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
ZIOPTAN's oppositions filed in EPO
ZIOPTAN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5886035 | THEA | Difluoroprostaglandin derivatives and their use |
Dec, 2017
(8 years ago) | |
| US10864159 | THEA | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(3 years from now) | |
| US9999593 | THEA | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 10, 2017 |
Drugs and Companies using TAFLUPROST ingredient
NCE-1 date: 11 February, 2016
Market Authorisation Date: 10 February, 2012
Dosage: SOLUTION/DROPS
How can I launch a generic of ZIOPTAN before it's drug patent expiration?
More Information on Dosage
ZIOPTAN family patents